Very oversold and very cheap... Im going long here.
All, ABCL is for massively oversold on weekly down so regardless how you feel about the stock (even though price target analysts are WAY higher) this is due for a rip. Not to mention this is a perfect situation for institutions to enter into ABCL at a pretty big discount from fair value etc. I am temporarily waiting next few days watch it extremely closely then...
Abcellera is undergoing a massive selloff in a zigzag pattern. Waves A and B are done, and wave C is usually 1.618 the length of wave A, especially since wave A is a leading diagonal. Expect further downside to the 6.30 region. Nevertheless, I do see a relief rally coming up soon, maybe around the 12.65 area.
IMO it should go up from now on, please do your own research i do this for fun so dont take me serious !!!
All, ABCL in a pretty solid spot here imo. Definitely need conformation of bottom here, candle looks to be a reversal possibly. I would look at 17-20$ calls OTM longer term or leveraged stock position hold long with a very tight stop loss. Could drop one more level. Just watch, slap some alerts on it but ABCL definitely imo worth 20-22.
I think last close was the bottom of ABCL downtrend. I bought the stock at $2.02. So, I think it would be the right time to buy NASDAQ:ABCL . DISCLAIMER ON . I'm just trying to share my analysis . Be wise with your money . Have a good day !
Hello! Friends, -This would be a great Buy Opportunity, IF NASDAQ:ABCL breaks up the Daily Resistance line at $27.70 (with a WHOLE DAILY Candle) !!
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes, and analyzes antibody responses to engineer new antibody drug candidates for its partners. If you want not to miss ideas like this one,🎯 subscribe and press a...
Actually a good chart position / funadmentals iBorrowdesk.com the short fee just doubled from 17 to 35 past 15 minutes. News 15 min ago : www.businesswire.com - Study was the first of its kind to show a neutralizing antibody can decrease SARS-CoV-2 viral shedding and transmission by blocking virus replication in the upper airway - Bamlanivimab moved from first...
Needs to break $45 to retest the high other wise dropping to mid 20$ range.
AbCellera might just be the one to surpass all recent IPOs and it is not getting the attention it deserves.